Claus Vogelmeier, MD: key facts
- Kind of voice
- Academic
- Role
- Pulmonologist, University Hospital Marburg, Germany
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 3
- Most recently quoted
- 30 Sept 2026
“chaired a panel discussion of how targeting distinct IL-33 pathways might change the future landscape of COPD”
What Claus Vogelmeier, MD has said
“It is worth trying to diagnose patients earlier because benefits can be quite impressive”
GOLD Science Committee Chair · Respiratory (asthma/COPD) · 30 Sept 2026 · 2026 GOLD COPD Update Emphasizes Early COPD Detection, Multimorbidity, AI ↗
“Mepolizumab Cuts COPD Exacerbations Across Smoking Status”
MD · Respiratory (asthma/COPD) · 28 Sept 2026 · Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD ↗
Where Claus Vogelmeier, MD has been quoted
- IL-33 Is Not Just IL-33: There Is More Than One Side to the COPD Storyemjreviews.com · 30 Sept 2026
- 2026 GOLD COPD Update Emphasizes Early COPD Detection, Multimorbidity, AIpulmonologyadvisor.com · 30 Sept 2026
- Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MDhcplive.com · 28 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.